Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era
Wang, Julia, Hwang, Steven, Durani, Urshila, Thanarajasingam, Gita, Khurana, Arushi, Paludo, Jonas, Wang, Yucai, Nowakowski, Grzegorz, Habermann, Thomas, Witzig, Thomas, Ansell, Stephen, Abeykoon, Jithma, Wang, Julia, Hwang, Steven, Durani, Urshila, Thanarajasingam, Gita, Khurana, Arushi, Paludo, Jonas, Wang, Yucai, Nowakowski, Grzegorz, Habermann, Thomas, Witzig, Thomas, Ansell, Stephen, Abeykoon, Jithma

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5399-5399

10.1182/blood-2025-5399 Get It

Abstract Introduction: Brentuximab vedotin (BV) was approved by the US FDA for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in 2011 and for previously untreated advanced stage cHL in 2018. The immune checkpoint inhibitors (ICIs) nivolumab and pembrolizumab were approved for R/R cHL in 2016 and 2017, respectively. These novel agents have significantly changed the landscape of cHL management in recent years. In this study, we analyzed data from the National Cancer Database (NCDB) to investigate whether survival outcomes have improved in the novel agent era (2011 and beyond) for patients with cHL in the US. Methods: Patients diagnosed with cHL between 2004 and 2020 were identified in the NCDB. Those with missing survival data were excluded. Three treatment eras were defined based on the timing of FDA approval of novel agents: Chemo era (2004–2010), BV era (2011–2015), and ICI era (2016–2020). Patient and disease characteristics were compared using the Chi-square test. Survival analyses were conducted using the Kaplan-Meier method and Cox proportional hazards model. Results: A total of 85,488 patients with newly diagnosed cHL were identified: 36,150 in the Chemo era, 27,058 in the BV era, and 22,280 in the ICI era. Compared to the chemo era, the BV and/or ICI eras included slightly more patients aged ≥66 (17.3% vs 17.8% vs 19.5%), male (53.6% vs 54.6% vs 53.8%, p=0.042), Black (11.3% vs 12.9% vs 12.5%), Hispanic (9.0% vs 9.9% vs 10.9%), with Charlson-Deyo score ≥1 (14.2% vs 16.1% vs 17.2%), B symptoms (44.1% vs 46.9% vs 46.9%), treated at academic centers (32.4% vs 35.9% vs 36.4%), on Medicaid (9.5% vs 12.2% vs 13.7%) or Medicare (19.3% vs 20.3% vs 21.7%), and with higher income (≥4th quartile by 2008-2012 standard; 34.5% vs 34.3% vs 36.3%) (all p<0.001 except for sex, noted above). Ann Arbor stage data were not available in the ICI era. There were slightly more patients with advanced-stage disease in the BV era compared to the Chemo era (45.4% vs 40.3%, p<0.001). IPS scores were available for only 2,344 patients, with a similar distribution (0–2 vs 3–7) across the three eras (p=0.957). The median follow-up was 6.9 years (95% CI 6.9-7.0). Overall survival (OS) significantly improved in the novel agent eras: the 5-year OS rate was 79.8% (95% CI, 79.4%–81.2%) for patients diagnosed in the Chemo era, 81.9% (95% CI, 81.9%–82.4%) in the BV era, and 84.1% (95% CI, 83.5%–84.8%) in the ICI era (p<0.001). Statistically significant OS improvements were observed across all subgroups, including age (≤40: 92.8% vs 94.9% vs 96.5%, 41-65: 80.5% vs 81.8% vs 84.4%, ≥66: 41.4% vs 46.6% vs 52.7%), sex (male: 78.0% vs 80.0% vs 81.9%, female: 81.9% vs 84.1% vs 86.7%), race (White: 79.9% vs 81.6% vs 83.7%, Black: 77.2% vs 81.2% vs 84.6%, others: 84.5% vs 87.0% vs 89.3%), ethnicity (Hispanic 79.7% vs 82.3% vs 85.1%, Non-Hispanic 80.0% vs 81.9% vs 84.1%), Charlson-Deyo score (0: 83.5% vs 85.4% vs 87.9%, 1: 62.8% vs 68.2% vs 73.2%, 2: 42.5% vs 52.6% vs 58.3%, 3+: 49.0% vs 54.4% vs 51.7%), B symptoms (yes: 74.7% vs 78.9% vs 81.5%, no: 84.3% vs 85.1% vs 87.5%), treatment facility type (academic: 69.8% vs 74.0% vs 77.1%, non-academic: 66.4% vs 67.6% vs 70.2%, unknown: 92.9% vs 95.0% vs 96.5%), insurance type (private: 89.9% vs 91.2% vs 93.4%, Medicare: 46.5% vs 52.3% vs 57.2%, Medicaid: 79.1% vs 84.5% vs 87.7%) and income level (Q1: 74.1% vs 77.1% vs 81.1%, Q2 77.7% vs 80.1% vs 81.3%, Q3 79.8% vs 81.6% vs 85.2%, Q4: 82.8% vs 84.9% vs 87.0%) (all p<0.001). In multivariate Cox regression analysis adjusting for age, sex, race, ethnicity, Charlson-Deyo score, B symptoms, treatment facility type, insurance type, and income level, diagnosis in the BV era (HR = 0.856; 95% CI, 0.827–0.885; p<0.001) and ICI era (HR = 0.666; 95% CI, 0.636–0.698; p<0.001) was independently associated with improved OS compared to the Chemo era. Conclusions: In this large NCDB-based analysis, survival outcomes for patients with cHL significantly improved in the BV and ICI eras compared to the Chemo era. OS improvement was consistent across all subgroups and remained independent of age, sex, race, ethnicity, Charlson-Deyo score, B symptoms, treatment facility type, insurance type, and income level in multivariate analysis. These findings may reflect the positive impact of BV and ICIs on survival in patients with cHL.
Genetic Testing in the Management of Adult CKD
Chebib, Fouad T. , Wang, Xiangling , Udani, Suneel M. , Westemeyer, Maggie , Clark, Dinah, Zhang, Zhiji, Rasouly, Hila Milo , Kolupaeva, Victoria, Mizani, Mohammad R. , Faravardeh, Arman , Kotte, Sri, Punj, Sumit , Chapman, Steven L. , Schneider, Ronen, Tabriziani, Hossein , Bhorade, Sangeeta , Gharavi, Ali G. , Kolupaeva, Victoria , Bloom, Michelle S , Milo Rasouly, Hila , Mizani, Mohammad R , Dossabhoy, Neville R , Faravardeh, Arman , Demko, Zachary P , Punj, Sumit , Chapman, Steven L , Rabinowitz, Matthew , Tabriziani, Hossein , Bhorade, Sangeeta , Dahl, Neera K , Westemeyer, Maggie , Kolupaeva, Victoria , Chebib, Fouad T , Wang, Xiangling , Udani, Suneel M. , Clark, Dinah, Zhang, Zhiji, Kotte, Sri, Schneider, Ronen, Gharavi, Ali G.

Mayo Clinic

Journal of the American Society of Nephrology | December 3, 2025 | Volume: 37 | Issue: 4 | Pages: 777-789

10.1681/asn.0000000913 | PMID 41563380 Get It

Key Points Genetic testing in CKD showed diagnostic and clinical utility in the year following reporting of test results. Genetic testing was helpful for or changed management in 86% of patients with a positive finding and 42% with a negative finding. Clinical utility was seen across 12 clinical cohorts, including CKD of unknown etiology and hypertension or diabetes-related nephropathy. Background CKD is a significant public health burden, affecting >800 million people worldwide with significant cost to the health care system. CKD is a disease process with substantial genetic and phenotypic heterogeneity that can obscure a definitive diagnosis, resulting in suboptimal management. Recent guidelines support greater adoption of genetic testing in CKD. We assessed the diagnostic and clinical utility in the year following broad-panel CKD genetic testing. Methods The Renasight Clinical Application, Review, and Evaluation (RenaCARE) study (NCT05846113) was a single-arm, interventional, prospective, multicenter study evaluating the utility of genetic testing with a 385-gene panel on the diagnosis and management of CKD. Clinical history was collected before testing, and nephrologists responded to questionnaires at both 1 month and 1 year after testing. The impact of genetic testing on CKD diagnosis and management were assessed in active study patients at the 1-year time point. Results In a cohort of 1388 CKD patients with 13 pretest clinical categories of CKD, 335 (24%) patients had a positive genetic finding; 1174 had a questionnaire completed at 1 year and were included in the analysis. Genetic testing was reported helpful for clinical management and/or led to a change in management in 86% of patients with a positive test finding and 42% of patients with a negative test finding. In addition, genetic testing resulted in a change in the physician estimation of the 5-year prognosis for 55% of patients with a positive test finding and 18% of those with a negative test finding. Conclusions Supporting the previous results of the RenaCARE study at 1 month, this report demonstrated that genetic testing was helpful in the clinical management and estimated prognosis of patients with CKD. Clinical Trial registry name and registration number: ClinicalTrials.gov, NCT05846113.
Safety and Efficacy in Pediatric Patients with Relapsed/Refractory Classic Hodgkin Lymphoma enrolled on an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin (E4412)
Wang, Victoria , Ansell, Stephen M. , Mehta-Shah, N, Amengual, Jennifer E. , Cole, Peter D. , Forlenza, Christopher J. , Jegede, O, Steidl, Christian , Natkunam, Yasodha , Scott, David W. , Kahl, Brad S. , Diefenbach, Catherine

Mayo Clinic

Klinische Pädiatrie | December 3, 2025 | Volume: 237 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1812988 Get It

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Maurer, Matthew J. , Procházka, Vít , Flowers, Christopher R. , Villa, Diego , Bachy, Emmanuel , Cahn, Elliot, Fournier, Marguerite , Larson, Melissa C. , Dietrich, Caroline E. , Ghesquières, Hervé , Gandhi, Maher K. , Cheah, Chan Y. , Hawkes, Eliza A. , Seymour, John F. , Freeman, Ciara L. , Friedberg, Jonathan W. , Casulo, Carla , Móciková, Heidi , Fürst, Tomáš, Feugier, Pierre, Tilly, Hervé , Davies, Andrew , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Smedby, Karin E. , Prochazka, Vit , Flowers, Christopher R , Villa, Diego , Bachy, Emmanuel , Cahn, Elliot J, Fournier, Marguerite , Larson, Melissa C , Dietrich, Caroline E , Kridel, Robert , Gandhi, Maher K , Cheah, Chan Yoon , Hawkes, Eliza , Seymour, John F , Clausen, Michael Roost , Casulo, Carla , Habermann, Thomas , Wang, Yucai , Nastoupil, Loretta J , de Nully Brown, Peter , Janikova, Andrea , Tilly, Hervé , Davies, Andrew , Cartron, Guillaume , Burack, W Richard , Chihara, Dai , Martin, Peter , Cohen, Jonathon B , Lossos, Izidore S , Kahl, Brad S , Sehn, Laurie H , E Smedby, Karin , Salles, Gilles A , Trnĕný, Marek , Link, Brian K , Morschhauser, Franck , Cerhan, James R , Maurer, Matthew , El‐Galaly, Tarec Christoffer , Jakobsen, Lasse Hjort , Clausen, Michael Roost , Wahlin, Björn , Casulo, Carla , Habermann, Thomas M. , Wang, Yucai , Nastoupil, Loretta J. , Brown, Peter de Nully , Belada, David , Feugier, Pierre , Haïoun, Corinne , Burack, Richard , Chihara, Dai , Kahl, Brad S. , Sehn, Laurie H. , Salles, Gilles , Trněný, Marek , Link, Brian K. , Morschhauser, Franck , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | December 2, 2025 | Volume: 44 | Issue: 2 | Pages: 117-128

10.1200/jco-25-00892 | PMID 41329901 Get It

PURPOSE Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074). RESULTS The FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL. CONCLUSION The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.
Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study
Feldman, Andrew L. , Dasari, Surendra, Scott, David W. , Oishi, Naoki , Hu, Guangzhen , Farinha, Pedro , Amador, Catalina , Campo, Elı́as , Cook, James R. , Fu, Kai , Greiner, Timothy C. , Iqbal, Javeed , Ondrejka, Sarah L. , Ott, G., Rosenwald, Andreas , Slack, Graham W. , Wright, George, Zeng, Yu , Yoshino, Tadashi, Wu, Xiaojun , Satou, Akira , Perry, Anamarija M. , Mou, Eric , Ko, Young Hyeh , Jiang, Liuyan , Gru, Alejandro A. , Chen, Weina , Chapman, Jennifer R. , Ansell, Stephen M. , Aljudi, Ahmed Assim , Scott, David W , Oishi, Naoki , Farinha, Pedro , Amador, Catalina , Campo, Elías , Cook, James R , Delabie, Jan , Greiner, Timothy C , Hilton, Laura K , Inghirami, Giorgio , Jaffe, Elaine S , Morin, Ryan D , Ondrejka, Sarah , Pittaluga, Stefania , Savage, Kerry J , Slager, Susan L , Wang, Hao-Wei , Wu, Xiaojun , Wilcox, Ryan A , Shi, Min , Miranda, Roberto N , Medeiros, L Jeffrey , Maurer, Matthew , Mou, Eric , Karube, Kennosuke , Gru, Alejandro , de Leval, Laurence , Chen, Weina , Cerhan, James R , Barrionuevo, Carlos , Aljudi, Ahmed Assim , Feldman, Andrew L , Iqbal, Javeed , Rimsza, Lisa M. , Chan, Wing C., Delabie, Jan , Hilton, Laura K. , Inghirami, Giorgio , Jaffe, Elaine S. , Pittaluga, Stefania , Raess, Philipp W. , Savage, Kerry J. , Slager, Susan L. , Song, Joo Y. , Wang, Hao‐Wei , Wilcox, Ryan A. , Wang, Xueju , Miranda, Roberto N. , Medeiros, L. Jeffrey , Maurer, Matthew J. , Karube, Kennosuke , Kahl, Brad S. , Jaye, David L. , Leval, Laurence de , Cerhan, James R.

Mayo Clinic

Blood | December 2, 2025 | Volume: 147 | Issue: 11 | Pages: 1199-1214

10.1182/blood.2024027700 | PMID 41329859 Get It

Abstract Anaplastic large cell lymphomas (ALCLs) are CD30+ T-cell lymphomas that share pathologic features but differ in presentation, outcome, and genetics. Current classification incorporates clinical presentation and anaplastic lymphoma kinase (ALK) status but inadequately addresses molecular heterogeneity and therapeutic vulnerabilities. We studied 689 patients with ALCL in the LLMPP (Lymphoma/Leukemia Molecular Profiling Project) and performed expert consensus review, genetic subtyping (ALK, DUSP22, TP63, and triple negative), and immunohistochemistry for phosphorylated STAT3Tyr705. RNA sequencing with unsupervised gene expression profiling in 393 patients identified 2 main molecular types of ALCL that could be predicted with 91% accuracy based on the presence (type I) or absence (type II) of phosphorylated STAT3Y705 expression. Type I ALCLs included ALK+ ALCL and a subset of triple-negative ALCLs (TN-I); type II ALCLs included tumors with DUSP22 and/or TP63 rearrangements and the remaining triple-negative ALCLs (TN-II). Type I ALCLs were enriched for JAK-STAT3, whereas type II ALCLs were enriched for non–tyrosine kinase pathways, particularly epigenetic regulators such as EZH2. Immunohistochemistry showed overexpression of EZH2 and its trimethylated substrate H3K27. Prognosis in systemic ALCL was favorable for DUSP22-rearranged ALCL (5-year overall survival, 95%) and ALK+ ALCL (88%), intermediate for triple-negative ALCL (TN-I, 52% and TN-II, 37%), and poor for TP63-rearranged ALCL (0%). We introduce an integrated molecular classification that preserves currently diagnosed ALCL entities but identifies 4 molecularly distinct ALK− ALCL subtypes (DUSP22-rearranged, TP63-rearranged, TN-I, and TN-II). This classification can be easily implemented on paraffin tissue in routine practice or clinical trials, and stratifies ALCL into diagnostically, prognostically, biologically, and potentially therapeutically relevant subtypes.
Abstract 188: Retinal venular diameter as an indicator of Alzheimer's‐associated vasculopathy
Pitea, R., Wang, V., Nitu, M. E., Li, X., Langlais, B., Dumitrascu, O. M., Pitea, R., Wang, V., Nitu, M. E., Li, X., Langlais, B., Dumitrascu, O. M.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_188 Get It

Introduction The association between retinal vessel diameters and cerebrovascular disease is well known. Additionally, retinal vascular measures provide a direct and objective modality to study Alzheimer's disease (AD) ‐ associated vasculopathy. Herein, we aimed to study the association between automatically quantified retinal arteries and veins diameters and AD. Methods We have identified 1039 subjects from the UK Biobank that had good‐quality macula‐centered color fundus photographs (220 with AD, 202 with Parkinson's disease (PD), 516 normal controls (NC)), of which 86.9% were right and 71.2% left eyes. We quantified retinal vascular measures in Hubbard zones B and C (central retinal vein equivalent (CRVE), central retinal artery equivalent (CRAE) and arterio‐venous ratio (AVR)) using Automorph. We assessed inter‐eye correlation between the vascular features using Spearman correlation coefficient. We adjusted for confounding patient characteristics between groups where present (age, gender, hypertension, diabetes mellitus (DM)) and the presence of APOE4 carrier allele. Group‐level adjusted mean estimates and mean differences for AD vs NC and AD vs PD with 95% confidence intervals (CI) were constructed using regression modeling. Results Subjects with AD were significantly older than NC (mean (SD) age 64.9(4.4) vs 55.9(8.1) years, p<0.001), had similar gender distribution, similar incidence of hypertension (27.7% vs 22.7%, p=0.1428), significantly more DM (6.8% vs 3.5%, p=0.04) and more likely to be APOE4 carriers (64.4% vs 30.8%, p<0.001). When compared to PD subjects, AD were older (mean (SD) age 64.9 (4.4) vs 62.6 (5.3) years, p<0.001), less commonly male (46.4% vs 61.4%, p=0. 0007), had similar incidence of hypertension (27.7% vs 31.0%, p=0.4152) and DM (6.8% vs 6.3%, p=0. 8020) but were more likely to be APOE4 carriers (64.4% vs 29.6%, p<0.001). All CRAE, CRVE, and AVR measures showed significant correlations between right and left eyes, hence we report only right eye measures given greater sample size. Between AD and NC, age and DM adjusted retinal vascular measures showed greater CRVE in Hubbard zone B (mean difference (CI) 2.042 (0.61, 3.47), p=0.005) and zone C (mean difference (CI) 1.859 (0.41, 3.29), p =0.01). After additional adjustment for APOE4, CRVE in zone B only remained significantly greater in AD when compared to NC (mean difference (CI) 1.97 (0.15, 3.79), p=0.03). When we compared AD and PD subjects, age and gender adjusted retinal vascular measures also exhibited greater CRVE in AD in both zones B and C, that remained significant after additional adjustment for APOE carrier status (mean difference (CI) 2.531 (0.946, 4.117), p=0.0018). CRAE and AVR showed non‐significant differences between AD and NC, as well as AD and PD, in all zones (p>0.05 for all comparisons). Conclusions The central retinal vein equivalent was significantly greater in subjects with AD in the UK Biobank, after adjusting for demographic, vascular co‐morbidities and APOE4 carrier status. These results suggest that wider retinal venules are indicators of AD‐associated retinal vasculopathy and degeneration.
Abstract 147: Retinal Vascular Alterations Discriminate Subjects with Neurodegeneration in the UK Biobank
Wang, V. , Dumitrașcu, Oana , Chen, Kewei

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_147 Get It

Background Retinal vascular imaging offers a non‐invasive window into the central nervous system health and has shown promise in the study of neurodegenerative diseases. Emerging evidence highlights that Parkinson's disease (PD) exhibits structural and functional changes in the retina, including vascular alterations. This pilot study evaluated whether retinal vascular morphological features, quantified using the deep learning tool Automorph, discriminate PD from non‐PD subjects in the UK Biobank cohort. Methods We analyzed color fundus photographs (CFPs) from 303 PD participants (mean age 62.6 ± 5.4 years, hypertension (HTN) = 67%, diabetes mellitus (DM) = 13%) and 516 non‐PD controls (age = 55.9±8.1, HTN = 22.8%, DM = 3%) enrolled in the UK Biobank. Six retinal vascular morphology features were quantified: fractal dimension, vessel density, average width, distance tortuosity, squared curvature tortuosity, and tortuosity density. General linear models were used to assess group differences while adjusting for age, hypertension, and diabetes. We also evaluated the association between retinal features and age, and the left‐right eye retinal fractal measures correlations using Pearson correlation and Fisher Z‐test. Results Compared to non‐PD individuals, PD patients showed significantly altered retinal vessel average width, both without (p = 0.001) and with (p = 0.002) vascular covariate adjustment. Group‐by‐age interaction effects were also significant for fractal dimension (p = 0.010) and vessel density (p = 0.023). Furthermore, inter‐eye correlation of vessel density differed significantly between groups (p = 0.034), suggesting altered bilateral vascular symmetry in PD. Conclusion Measurable alterations in retinal vascular morphology in PD support the potential of retina vascular imaging for non‐invasive neurodegenerative disease research. These results warrant further validation in larger cohorts, with improved analytic robustness and automated retinal vascular grading.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Walbert, Tobias , Lassman, Andrew B. , Peereboom, David M. , Kizilbash, Sani H. , Matsuoka, Carlos Kamiya , Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Butowski, Nicholas , Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Wang, Chao , Levin, Victor A. , Lassman, Andrew B , Peereboom, David M , Kizilbash, Sani H , Kamiya-Matsuoka, Carlos , Pitz, Marshall W , Strowd, Roy E , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Soffietti, Riccardo , Butowski, Nicholas A , Forsyth, Peter A , Hamza, Mohamed A , Hau, Peter , Nabors, Louis Burt , Uhlmann, Erik J , Welsh, Liam C , Wen, Patrick Yung , Dietrich, Jorg , Wang, Chao , Levin, Victor A , Colman, Howard , Eoli, Marica , Strowd, Roy E. , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Lombardi, G

Mayo Clinic

Journal of Clinical Oncology | December 1, 2025 | Volume: 44 | Issue: 8 | Pages: 641-652

10.1200/jco-25-01204 | PMID 41325560 Get It

PURPOSE STELLAR (ClinicalTrials.gov identifier: NCT02796261 ) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase ( IDH ) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m 2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m 2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m 2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH- mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH -mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
Impact of CKD on Angiodysplasia-Related Gastrointestinal Bleeding: Incidence, Outcomes, and Readmission Risk in a National Cohort
He, Mingyue , Shah, Ankur , Wang, Yichen , Gillespie, Avrum

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025rhhvc128 Get It

Dysregulation of the Plasma Metabolome Profile in Kidney Stone Formers
Zhou, Le‐Ting , Rule, Andrew D., Koo, Kevin , Lieske, John C., Wang, Liang , Rule, Andrew D. , Larson, Nicholas B. , Harris, Peter C. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.20256pg8x3gr Get It